UK Markets close in 7 hrs 44 mins

Zealand Pharma A/S (ZEAL.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
94.10-0.40 (-0.42%)
As of 09:39AM CEST. Market open.
Full screen
Previous close94.50
Open96.05
Bid93.90 x 0
Ask94.15 x 0
Day's range93.70 - 96.05
52-week range69.55 - 213.00
Volume7,982
Avg. volume237,809
Market cap4.067B
Beta (5Y monthly)1.16
PE ratio (TTM)N/A
EPS (TTM)-26.50
Earnings date09 Mar 2022 - 14 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est210.23
  • Globe Newswire

    Total number of shares and voting rights in Zealand Pharma at June 30, 2022

    Company announcement – No. 30 / 2022 Total number of shares and voting rights in Zealand Pharma at June 30, 2022 Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at the end of a

  • Globe Newswire

    Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities

    Company announcement – No. 29 / 2022 Transactions in Zealand Pharma A/S securities by persons discharging managerial responsibilities Copenhagen, DK and Boston, MA, June 15, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has received information on transactions in Zealand shares or related securities by persons discharging manager

  • Globe Newswire

    Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022

    Company announcement – No. 28 / 2022 Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders: Credit Suis